JSPR: Jasper Therapeutics, Inc. Stock

by  •  • Comments Off on JSPR: Jasper Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 93.16
Enterprise Value ($M) 0.66
Book Value ($M) 83.68
Book Value / Share 5.58
Price / Book 1.11
NCAV ($M) 79.07
NCAV / Share 5.27
Price / NCAV 1.18

Profitability (mra)
Return on Invested Capital (ROIC) -0.74
Return on Assets (ROA) -0.67
Return on Equity (ROE) -0.81

Liquidity (mrq)
Quick Ratio 7.61
Current Ratio 7.61

Balance Sheet (mrq) ($M)
Current Assets 94.81
Assets 99.41
Liabilities 15.73
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Avidity Partners Management LP 0.00 -100.00
11-14 13G/A Soleus Private Equity Fund III, L.P. 9.00
11-08 13G BlackRock, Inc. 5.30 0.00
11-04 13G/A Sphera Funds Management Ltd. 1.25
02-14 13G/A Qiming U.S. Healthcare Fund II, L.P. 6.20
02-09 13D/A Velan Capital Investment Management LP 9.80
2024-02-02 13G/A Soleus Capital Master Fund, L.P. 8.80

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-03-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 148,191 384,839 38.51
2025-02-03 88,068 290,775 30.29
2025-01-31 179,752 707,460 25.41
2025-01-30 384,101 1,053,432 36.46

(click for more detail)

Similar Companies
IRD – Opus Genetics, Inc. ITRM – Iterum Therapeutics plc
JAGX – Jaguar Health, Inc. KALA – KALA BIO, Inc.
KPRX – Kiora Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io